JP4170990B2 - Process for producing optically active serine derivatives - Google Patents
Process for producing optically active serine derivatives Download PDFInfo
- Publication number
- JP4170990B2 JP4170990B2 JP2005007362A JP2005007362A JP4170990B2 JP 4170990 B2 JP4170990 B2 JP 4170990B2 JP 2005007362 A JP2005007362 A JP 2005007362A JP 2005007362 A JP2005007362 A JP 2005007362A JP 4170990 B2 JP4170990 B2 JP 4170990B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- acid
- alkyl
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 13
- 150000003354 serine derivatives Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 44
- 238000004519 manufacturing process Methods 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 16
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 14
- 239000012965 benzophenone Substances 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- -1 alkali metal alkoxide Chemical class 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 239000003495 polar organic solvent Substances 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 238000005805 hydroxylation reaction Methods 0.000 claims description 6
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 claims description 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 4
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 4
- 229930182820 D-proline Natural products 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims description 4
- 229940073608 benzyl chloride Drugs 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 description 18
- 229960001104 droxidopa Drugs 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XDDLXZHBWVFPRG-UHFFFAOYSA-N 3,4-bis(phenylmethoxy)benzaldehyde Chemical compound C=1C=CC=CC=1COC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 XDDLXZHBWVFPRG-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000005882 aldol condensation reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- XNROFTAJEGCDCT-LLVKDONJSA-N (2r)-1-benzylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCN1CC1=CC=CC=C1 XNROFTAJEGCDCT-LLVKDONJSA-N 0.000 description 1
- RGCLHVKCJVVHLN-QMMMGPOBSA-N (2s)-2-acetamido-3-(3,4-dihydroxyphenyl)propanoic acid Chemical class CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C(O)=C1 RGCLHVKCJVVHLN-QMMMGPOBSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- IBGBGRVKPALMCQ-UHFFFAOYSA-N Oc(ccc(C=O)c1)c1O Chemical compound Oc(ccc(C=O)c1)c1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
- E04G25/00—Shores or struts; Chocks
- E04G25/04—Shores or struts; Chocks telescopic
- E04G25/06—Shores or struts; Chocks telescopic with parts held together by positive means
- E04G25/061—Shores or struts; Chocks telescopic with parts held together by positive means by pins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
- E04G1/00—Scaffolds primarily resting on the ground
- E04G1/02—Scaffolds primarily resting on the ground composed essentially of members elongated in one dimension only, e.g. poles, lattice masts, with or without end portions of special form, connected together by any means
- E04G1/04—Scaffolds primarily resting on the ground composed essentially of members elongated in one dimension only, e.g. poles, lattice masts, with or without end portions of special form, connected together by any means the members being exclusively poles, rods, beams, or other members of similar form and simple cross-section
- E04G1/06—Scaffolds primarily resting on the ground composed essentially of members elongated in one dimension only, e.g. poles, lattice masts, with or without end portions of special form, connected together by any means the members being exclusively poles, rods, beams, or other members of similar form and simple cross-section comprising members with rod-like or tubular portions fitting together end to end, with or without separate connecting pieces
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
- E04G7/00—Connections between parts of the scaffold
- E04G7/30—Scaffolding bars or members with non-detachably fixed coupling elements
- E04G7/302—Scaffolding bars or members with non-detachably fixed coupling elements for connecting crossing or intersecting bars or members
- E04G7/306—Scaffolding bars or members with non-detachably fixed coupling elements for connecting crossing or intersecting bars or members the added coupling elements are fixed at several bars or members to connect
- E04G7/307—Scaffolding bars or members with non-detachably fixed coupling elements for connecting crossing or intersecting bars or members the added coupling elements are fixed at several bars or members to connect with tying means for connecting the bars or members
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
- E04G7/00—Connections between parts of the scaffold
- E04G7/30—Scaffolding bars or members with non-detachably fixed coupling elements
- E04G7/34—Scaffolding bars or members with non-detachably fixed coupling elements with coupling elements using positive engagement, e.g. hooks or pins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Architecture (AREA)
- Mechanical Engineering (AREA)
- Civil Engineering (AREA)
- Structural Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
本発明は光学的に活性であるセリン誘導体の製造方法に関するもので、さらに詳しくにはドロキシドパと知られた光学的に活性であるセリン誘導体またはその塩の製造方法、及びその製造中間体に関する。 The present invention relates to a method for producing an optically active serine derivative, and more particularly to a method for producing an optically active serine derivative known as droxidopa or a salt thereof, and a production intermediate thereof.
ドロキシドパまたはその塩は、循環系及び中枢神経系に活性を有し、パーキンソン病、憂鬱症、末梢起立性低血圧などの治療剤として有用な薬物である。ドロキシドパは、光学的に活性であるセリン誘導体であって、その化学名は、L−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンであり、下記化学式1aの構造を有する。 Droxidopa or a salt thereof is active in the circulatory system and central nervous system, and is a useful drug as a therapeutic agent for Parkinson's disease, depression, peripheral orthostatic hypotension and the like. Droxidopa is an optically active serine derivative, whose chemical name is L-threo- (2S, 3R) -3- (3,4-dihydroxyphenyl) serine, and has the structure of the following chemical formula 1a: Have.
特許文献1(特許文献2、3、4)は、4種の異性体からドロキシドパを含むそれぞれの異性体を分離する方法を開示している。しかし、4種の異性体から分離を行うことによって、最大収率が25%を超過できないという問題点がある。 Patent Document 1 (Patent Documents 2, 3, and 4) discloses a method for separating each isomer including droxidopa from four kinds of isomers. However, there is a problem that the maximum yield cannot exceed 25% by separating from the four isomers.
また、特許文献5は、ドパ(DOPA)から得られたN−アセチルドパ誘導体からドロキシドパを製造する方法を開示している。しかし、この方法は、高価な試薬であるドパを使用することによって、高い製造コストが所要される短所がある。 Patent Document 5 discloses a method for producing droxidopa from an N-acetyldopa derivative obtained from dopa (DOPA). However, this method has a disadvantage that high production cost is required by using dopa, which is an expensive reagent.
特許文献6は、キラルジオール誘導体を合成した後、アジド基を導入しかつ還元させて、ドロキシドパを製造する方法を開示しており、特許文献7及び8は、ベンズアルデヒド誘導体を出発物質として使用してスレオ−N−フタロイル−3−(3,4−ジヒドロキシフェニル)セリンを製造した後、ドロキシドパを製造する方法を開示している。しかし、商業的な規模の量産及び収率の側面で新たな製造方法の開発が当業界に要求される。 Patent Document 6 discloses a method of synthesizing a chiral diol derivative and then introducing and reducing an azide group to produce droxidopa. Patent Documents 7 and 8 use a benzaldehyde derivative as a starting material. A method for producing droxidopa after producing threo-N-phthaloyl-3- (3,4-dihydroxyphenyl) serine is disclosed. However, there is a need in the art to develop new manufacturing methods in terms of commercial scale mass production and yield.
一方、非特許文献1は、アルデヒド及びケトンをグリシンと縮合してジアステレオ及びエナンチオ選択性β−ヒドロキシ−α−アミノ酸の製造方法を開示している。すなわち、下記の構造式を有するグリシン及び金属のキラル錯物を、アルデヒド及びケトンと反応させてD−スレオ−(2R,3S)−β−フェニルセリン誘導体を製造する方法を開示している。 On the other hand, Non-Patent Document 1 discloses a method for producing diastereo and enantioselective β-hydroxy-α-amino acids by condensing an aldehyde and a ketone with glycine. That is, a method of producing a D-threo- (2R, 3S) -β-phenylserine derivative by reacting a chiral complex of glycine and metal having the following structural formula with an aldehyde and a ketone is disclosed.
また、非特許文献2は、前記キラル錯物を利用して側鎖にフッ素原子を有するβ−ヒドロキシ−α−アミノ酸の製造方法を開示している。 Non-Patent Document 2 discloses a method for producing a β-hydroxy-α-amino acid having a fluorine atom in a side chain using the chiral complex.
しかし、前記先行技術(すなわち、非特許文献1または2)を利用して光学的に活性であるセリン誘導体を製造しようとする場合、D−スレオ−(2R,3S)−3−(3,4−ジヒドロキシフェニル)セリンが主に得られ、ドロキシドパであるL−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンは、純粋に得るのが非常に困難である。さらに、前記先行技術によってドロキシドパを製造する場合、トリエチルアミンとメタノールとの混合溶媒での反応時間が3日以上かかり、スレオ−(2S,3R)型及びエリトロ−(2S,3S)型の1:1〜2:1混合物が生成され、(2R,3S)及び(2R,3R)の混合物も5〜20%生成されることによって、純粋な目的化合物であるL−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリン、すなわち、ドロキシドパの製造のための商業的な適用は非常に難しいという問題点がある。 However, when an optically active serine derivative is to be produced using the prior art (that is, Non-Patent Document 1 or 2), D-threo- (2R, 3S) -3- (3,4 -Dihydroxyphenyl) serine is mainly obtained, and droxidopa L-threo- (2S, 3R) -3- (3,4-dihydroxyphenyl) serine is very difficult to obtain purely. Further, when droxidopa is produced by the above prior art, the reaction time in a mixed solvent of triethylamine and methanol takes 3 days or more, and the threo- (2S, 3R) type and erythro- (2S, 3S) type 1: 1. A pure target compound, L-threo- (2S, 3R) -3, is produced by producing a ˜2: 1 mixture and also producing a 5-20% mixture of (2R, 3S) and (2R, 3R). The commercial application for the production of-(3,4-dihydroxyphenyl) serine, ie droxidopa, is very difficult.
また、前記先行技術によってドロキシドパを製造する場合、フェニル環に存在する2個のヒドロキシ基によって反応(すなわち、アルドール縮合反応)自体が進められないという問題点がある。
本発明は、高い光学的純度を有するドロキシドパを高い収率で製造できる新たな製造方法及びその中間体を提供する。すなわち、本発明は、L−スレオ−(2S,3R)−β−ヒドロキシ−α−アミノ酸の立体化学を有するドロキシドパを高い純度と高い収率とで製造する立体選択的な製造方法及びその中間体として有用なキラル金属錯物を提供する。 The present invention provides a new production method capable of producing droxidopa having high optical purity in a high yield and an intermediate thereof. That is, the present invention relates to a stereoselective production method for producing droxidopa having the stereochemistry of L-threo- (2S, 3R) -β-hydroxy-α-amino acid with high purity and high yield, and an intermediate thereof. The present invention provides a chiral metal complex useful as:
したがって、本発明は、ドロキシドパの製造方法を提供することを目的とする。 Accordingly, an object of the present invention is to provide a method for producing droxidopa.
また、本発明の目的は、ドロキシドパの製造中間体として有用な中間体を提供することを含む。 Moreover, the objective of this invention includes providing an intermediate useful as a manufacturing intermediate of droxidopa.
本発明の一様相は、化学式2の化合物を極性有機溶媒中で酸で分解させて化学式1bの化合物を得る段階と、前記化学式1bの化合物のヒドロキシル化反応を行う段階と、を含むL−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンまたはその塩の製造方法を提供する。 The uniform phase of the present invention includes a step of decomposing a compound of Formula 2 with an acid in a polar organic solvent to obtain a compound of Formula 1b, and performing a hydroxylation reaction of the compound of Formula 1b. A method for producing-(2S, 3R) -3- (3,4-dihydroxyphenyl) serine or a salt thereof is provided.
式中、R1及びR2は、それぞれ独立的に、ベンジル、p−ニトロベンジル、p−フルオロベンジル、p−トリフロオロベンジル、C1〜C4アルコキシC1〜C4アルキル、またはC1〜C4アルキルであり、MはCu2+、Ni2+、またはZn2+である。 In the formula, R 1 and R 2 are each independently benzyl, p-nitrobenzyl, p-fluorobenzyl, p-trifluorobenzyl, C 1 -C 4 alkoxy C 1 -C 4 alkyl, or C 1. a -C 4 alkyl, M is Cu 2+, a Ni 2+, or Zn 2+.
本発明の他の様相は、下記化学式2の化合物を提供する。 Another aspect of the present invention provides a compound of formula 2 below.
式中、R1、R2、及びMは、前記の通りである。 In the formula, R 1 , R 2 , and M are as described above.
本発明は、本発明のさらに他の様相は、下記の化学式3の化合物を提供する。 According to another aspect of the present invention, there is provided a compound represented by Formula 3 below.
式中、Mは、前記の通りである。 In the formula, M is as described above.
本発明の製造方法は、低価の反応試薬を使用して高純度及び高収率でL−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンまたはその塩を製造でき、化学式2及び/または化学式3の化合物は、ドロキシドパの製造中間体として有用に使用されうる。 The production method of the present invention can produce L-threo- (2S, 3R) -3- (3,4-dihydroxyphenyl) serine or a salt thereof with high purity and high yield using a low-valent reaction reagent. The compound of Chemical Formula 2 and / or Chemical Formula 3 can be usefully used as an intermediate for producing droxidopa.
本発明の一態様によって、化学式2の化合物を極性有機溶媒中で酸で分解して化学式1bの化合物を得る段階と、前記化学式1bの化合物のヒドロキシル化反応を行う段階と、を含む、ドロキシドパ(すなわち、L−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリン)またはその塩の製造方法が提供される。 According to one embodiment of the present invention, a step of decomposing a compound of Formula 2 with an acid in a polar organic solvent to obtain a compound of Formula 1b and performing a hydroxylation reaction of the compound of Formula 1b include droxidopa ( That is, a process for producing L-threo- (2S, 3R) -3- (3,4-dihydroxyphenyl) serine) or a salt thereof is provided.
式中、R1及びR2は、それぞれ独立的に、ベンジル、p−ニトロベンジル、p−フルオロベンジル、p−トリフルオロベンジル、C1〜C4アルコキシC1〜C4アルキル、またはC1〜C4アルキルであり、Mは、Cu2+、Ni2+、またはZn2+である。 In the formula, R 1 and R 2 are each independently benzyl, p-nitrobenzyl, p-fluorobenzyl, p-trifluorobenzyl, C 1 -C 4 alkoxy C 1 -C 4 alkyl, or C 1- C 4 alkyl and M is Cu 2+ , Ni 2+ , or Zn 2+ .
本発明の製造方法において、R1及びR2が何れもベンジルである場合、ヒドロキシル化反応を容易に進めうるので望ましい。 In the production method of the present invention, when both R 1 and R 2 are benzyl, it is desirable because the hydroxylation reaction can be easily advanced.
本発明の製造方法において、前記極性有機溶媒としては、C1〜C7のアルコール、テトラヒドロフラン、アセトニトリル、ジメチルホルムアミド、及びこれらの混合溶媒よりなる群から選択され、望ましくはメタノールを使用しうる。また、化学式1bの化合物の製造に使われる前記酸としては、無機酸及び有機酸をいずれも使用でき、例えば、塩酸、臭化水素酸、硫酸、硝酸、酢酸、またはトリフルオロ酢酸を使用でき、望ましくは塩酸を使用できる。 In the production method of the present invention, the polar organic solvent is selected from the group consisting of C 1 to C 7 alcohols, tetrahydrofuran, acetonitrile, dimethylformamide, and mixed solvents thereof, and preferably methanol can be used. In addition, as the acid used to produce the compound of Formula 1b, any of inorganic acid and organic acid can be used, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, or trifluoroacetic acid can be used, Desirably, hydrochloric acid can be used.
前記酸の使用量は、使用する酸の種類によって異なるが、化学式2の化合物1当量に対して、約20当量以上、望ましくは約30当量を使用できる。前記化学式2の化合物の分解反応は−10〜100℃、望ましくは約50℃で行え、約10分〜5時間、望ましくは約1時間行える。 The amount of the acid used varies depending on the type of acid used, but about 20 equivalents or more, desirably about 30 equivalents, can be used with respect to 1 equivalent of the compound of Chemical Formula 2. The decomposition reaction of the compound of Formula 2 can be performed at -10 to 100 ° C, preferably about 50 ° C, for about 10 minutes to 5 hours, preferably about 1 hour.
分解反応後に残る中間体、すなわち、D−2−[N−(N'−ベンジルプロリル)
アミノ]ベンゾフェノンは90%以上回収が可能であり、ラセミ化が発生せず、次の反応に継続的に使用が可能であるので、経済的に非常に有利である。
Intermediate remaining after the decomposition reaction, ie D-2- [N- (N′-benzylprolyl)
Amino] benzophenone can be recovered more than 90%, does not cause racemization, and can be used continuously in the next reaction, which is very advantageous economically.
前記ヒドロキシル化反応は、通常のヒドロキシル化反応を使用でき、望ましくはPd/C、Ptなどの金属及び酸(例えば、HCl、HBrなど)存在下で水素を加えることによって行われうる。また、溶媒は、前記のような極性有機溶媒(例えば、エタノール)を使用して−10〜100℃、望ましくは約20℃で反応を行える。 The hydroxylation reaction may be performed by adding hydrogen in the presence of a metal such as Pd / C, Pt and an acid (eg, HCl, HBr, etc.). The solvent can be reacted at −10 to 100 ° C., preferably about 20 ° C., using a polar organic solvent (for example, ethanol) as described above.
本発明の製造方法で、前記化学式2の化合物は、化学式3の化合物と化学式4の化合物とを、塩基存在下で反応させて製造しうる。 In the production method of the present invention, the compound of the chemical formula 2 can be produced by reacting the compound of the chemical formula 3 and the compound of the chemical formula 4 in the presence of a base.
式中、R1、R2、及びMは、前記の通りである。 In the formula, R 1 , R 2 , and M are as described above.
前記塩基としては、水酸化ナトリウム、水酸化カリウム及び水酸化リチウムのようなアルカリ金属水酸化物;水酸化マグネシウム、水酸化カリウム及び水酸化バリウムのようなアルカリ土金属水酸化物;ナトリウムメトキシド、ナトリウムエトキシド及びカリウムt−ブトキシドのようなアルカリ金属アルコキシド;NHR3R4(R3及びR4は、同一または相異なり、それぞれC1〜C7のアルキルである);NH2R5(R5はC1〜C9のアルキルである);テトラブチルアンモニウムヒドロキシド及びベンジルトリメチルアンモニウムヒドロキシドのような4級アミン水酸化物;NaH;及びNaNH2よりなる群から選択されうる。このうち、立体選択性を最大限増大させるために、アルカリ金属アルコキシド(例えば、ナトリウムメトキシド)、NaH、またはNaNH2を望ましく使用できる。前記塩基の使用量は、使用する塩基の種類によって異なるが、化学式3の化合物1当量に対して、約3当量以上、望ましくは約7当量を使用できる。 Examples of the base include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide; alkaline earth metal hydroxides such as magnesium hydroxide, potassium hydroxide and barium hydroxide; sodium methoxide, Alkali metal alkoxides such as sodium ethoxide and potassium t-butoxide; NHR 3 R 4 (R 3 and R 4 are the same or different and each is C 1 -C 7 alkyl); NH 2 R 5 (R 5 is an alkyl of C 1 ~C 9); may be selected from the group consisting of NaNH 2; NaH; 4 amine hydroxides such as tetrabutylammonium hydroxide and benzyltrimethylammonium hydroxide. Of these, alkali metal alkoxide (for example, sodium methoxide), NaH, or NaNH 2 can be desirably used in order to maximize the stereoselectivity. The amount of the base used varies depending on the type of base used, but about 3 equivalents or more, desirably about 7 equivalents, can be used with respect to 1 equivalent of the compound of Chemical Formula 3.
化学式3の化合物と化学式4の化合物との反応は、非対称アルドール縮合反応であり、極性有機溶媒(例えば、前記極性有機溶媒、望ましくはメタノール)中で約1時間反応させて行える。化学式3の化合物1当量に対する化学式4の化合物の使用量は約1当量が望ましい。しかし、化学式4の化合物が相対的に低価であるので、化学式3の化合物に対して過量で使用することが望ましい。 The reaction between the compound of Formula 3 and the compound of Formula 4 is an asymmetric aldol condensation reaction and can be performed by reacting in a polar organic solvent (for example, the polar organic solvent, preferably methanol) for about 1 hour. The amount of the compound of formula 4 used is preferably about 1 equivalent per 1 equivalent of the compound of formula 3. However, since the compound of Chemical Formula 4 is relatively inexpensive, it is desirable to use it in an excess amount with respect to the compound of Chemical Formula 3.
前記化学式3の化合物は、D−プロリンとベンジルクロライドとを反応させてD−N−ベンジルプロリンを製造する段階と、前記D−N−ベンジルプロリンと2−アミノベンゾフェノンとを反応させてD−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾ
フェノンを製造する段階と、前記D−2−[N−(N'−ベンジルプロリル)アミノ]ベ
ンゾフェノン、M(すなわち、Cu2+、Ni2+、またはZn2+)を含む塩またはその水和物、及びグリシンを反応させる段階と、を含む方法で製造されうる。前記化学式3の化合物の製造方法を反応式で要約すれば、反応式1の通りである。
The compound of Formula 3 is prepared by reacting D-proline with benzyl chloride to produce DN-benzylproline, and reacting DN-benzylproline with 2-aminobenzophenone to form D-2. -[N- (N'-benzylprolyl) amino] benzophenone, and the D-2- [N- (N'-benzylprolyl) amino] benzophenone, M (ie, Cu 2+ , Ni 2+ or Zn 2+ ) or a hydrate thereof, and a step of reacting glycine. The production method of the compound of Chemical Formula 3 is summarized by Reaction Formula 1 as Reaction Formula 1.
D−プロリンとベンジルクロライドとを反応させてD−N−ベンジルプロリンを製造する段階は、水酸化カリウムなどの塩基存在下で、イソプロピルアルコールなどのアルコール中で行える。前記反応は、約40℃で約6時間で完了する。 The step of reacting D-proline with benzyl chloride to produce DN-benzylproline can be performed in an alcohol such as isopropyl alcohol in the presence of a base such as potassium hydroxide. The reaction is complete in about 6 hours at about 40 ° C.
前記D−N−ベンジルプロリンと2−アミノベンゾフェノンとを反応させてD−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノンを製造する段階は、塩化チ
オニル(SOCl2)存在下でジクロロメタンなどの通常の有機溶媒を使用して行える。すなわち、D−N−ベンジルプロリンのジジクロロメタン溶液を約−20〜−30℃に維持しつつ塩化チオニル(SOCl2)をゆっくり滴加した後、2−アミノベンゾフェノンを徐々に加えることによって反応を行える。
The step of reacting DN-benzylproline and 2-aminobenzophenone to produce D-2- [N- (N′-benzylprolyl) amino] benzophenone is performed in the presence of thionyl chloride (SOCl 2 ). This can be done using a normal organic solvent such as dichloromethane. That is, the reaction can be carried out by slowly adding thionyl chloride (SOCl 2 ) dropwise while maintaining a dichloromethane solution of DN-benzylproline at about −20 to −30 ° C. and then gradually adding 2-aminobenzophenone. .
また、前記D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノン、
M(すなわち、Cu2+、Ni2+、またはZn2+)を含む塩またはその水和物、及びグリシンを反応させる段階は、水酸化カリウムなどの塩基存在下でメタノールなどのアルコールを溶媒として使用して約40〜50℃で行える。前記Cu2+、Ni2+、またはZn2+を含む塩としては、硝酸塩形態(例えば、Ni(NO3)2など)、ハロゲン塩形態(例えば、NiCl2、NiBr2など)、アセテート形態(例えば、Ni(OAc)2など)、または硫酸塩形態(例えば、NiSO4など)でありうる。また、前記Cu2+、Ni2+、またはZn2+を含む塩の水和物としては多様な形態の水和物を使用でき、望ましくはNi(NO3)2・6H2Oを使用できる。
And D-2- [N- (N′-benzylprolyl) amino] benzophenone,
The step of reacting a salt containing M (that is, Cu 2+ , Ni 2+ , or Zn 2+ ) or a hydrate thereof and glycine is performed using an alcohol such as methanol in the presence of a base such as potassium hydroxide as a solvent. Can be used at about 40-50 ° C. Examples of the salt containing Cu 2+ , Ni 2+ , or Zn 2+ include nitrate form (eg, Ni (NO 3 ) 2 ), halogen salt form (eg, NiCl 2 , NiBr 2, etc.), acetate form ( For example, Ni (OAc) 2 ), or sulfate form (eg, NiSO 4 ). Further, as the hydrate of the salt containing Cu 2+ , Ni 2+ , or Zn 2+ , various forms of hydrate can be used, preferably Ni (NO 3 ) 2 .6H 2 O can be used. .
本発明の製造方法を、化学式3の化合物を出発物質として全体的な反応式で表すと、下記の反応式2に要約しうる。 The production method of the present invention can be summarized as the following reaction formula 2 when the compound of the chemical formula 3 is represented by the overall reaction formula using the starting material as a starting material.
本発明の他の態様によって、ドロキシドパの製造用中間体として有用な化学式2の化合物及び/または化学式3の化合物を提供する。
According to another aspect of the present invention, there is provided a compound of formula 2 and / or a compound of formula 3 useful as an intermediate for the production of droxidopa.
式中、R1、R2、及びMは、前記の通りである。 In the formula, R 1 , R 2 , and M are as described above.
以下、本発明を実施例を通じてさらに詳細に説明する。しかし、これら実施例は、本発明を例示するためのものであって、本発明が実施例によって限定されるものではない。 Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrating the present invention, and the present invention is not limited to the examples.
〔実施例1.D−N−ベンジルプロリンの製造〕
D−プロリン(115g,1mol)、水酸化カリウム(168.3g,3mol)、及びイソプロピルアルコール(1L)の懸濁液を40℃で攪拌した。懸濁液が透明になった後、ベンジルクロライド(137.3g,1.1mol)を徐々に添加して40℃で6時間攪拌した。反応液を0〜5℃に冷却した後、濃塩酸(145mL)でpHを5〜6に調節した。この反応液をクロロホルム(3L)で希釈して18時間攪拌した後、生成された塩化カリウムを濾過して除去した。濾液を濃縮してアセトンで再結晶して表記化合物161.8g(収率79%)を製造した。
[Example 1. Production of DN-benzylproline]
A suspension of D-proline (115 g, 1 mol), potassium hydroxide (168.3 g, 3 mol), and isopropyl alcohol (1 L) was stirred at 40 ° C. After the suspension became transparent, benzyl chloride (137.3 g, 1.1 mol) was gradually added and stirred at 40 ° C. for 6 hours. After the reaction solution was cooled to 0 to 5 ° C., the pH was adjusted to 5 to 6 with concentrated hydrochloric acid (145 mL). The reaction solution was diluted with chloroform (3 L) and stirred for 18 hours, and the produced potassium chloride was removed by filtration. The filtrate was concentrated and recrystallized with acetone to produce 161.8 g (yield 79%) of the title compound.
1H−NMR(CDCl3,ppm):δ7.2〜7.4(m,5H)、4.0〜4.4(dd,2H)、3.8(dd,1H)、3.6〜3.7(m,1H)、2.8(dd,1H)、1.8〜2.4(m,4H)
[α]D 25=+28.4(c=1,EtOH)
融点=174〜175℃
〔実施例2.D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノン
の製造〕
ジクロロメタン(500mL)中のD−N−ベンジルプロリン(100g,487mmol)溶液を−20〜−30℃に維持しつつ塩化チオニル(SOCl2)(35.5mL,487mmol)を徐々に滴加した。この反応液が透明になるまで−10℃を維持しつつ攪拌した後、2−アミノベンゾフェノン(86.5g,438mmol)のジクロロメタン(250mL)溶液を−30℃に維持しつつ徐々に滴加した。塩化アシルが反応上で消耗されたことが確認された後、0℃に冷却して炭酸ナトリウム水溶液を加えた。この反応液をジクロロメタンで抽出して蒸溜水及び飽和食塩水で洗浄した後、無水硫酸マグネシウムで乾燥して濃縮した。残渣をエタノールで再結晶及び濾過して表記化合物126g(収率74%)を製造した。
1 H-NMR (CDCl 3, ppm): δ7.2~7.4 (m, 5H), 4.0~4.4 (dd, 2H), 3.8 (dd, 1H), 3.6~ 3.7 (m, 1H), 2.8 (dd, 1H), 1.8-2.4 (m, 4H)
[Α] D 25 = + 28.4 (c = 1, EtOH)
Melting point = 174-175 ° C.
[Example 2. D-2- [Production of N- (N′-benzylprolyl) amino] benzophenone]
D-N-benzyl-proline (100 g, 487 mmol) in dichloromethane (500 mL) solution of thionyl chloride while maintaining -20 to-30 ° C. The (SOCl 2) (35.5mL, 487mmol ) was slowly added dropwise. The mixture was stirred while maintaining at −10 ° C. until the reaction solution became transparent, and then a solution of 2-aminobenzophenone (86.5 g, 438 mmol) in dichloromethane (250 mL) was gradually added dropwise while maintaining at −30 ° C. After confirming that the acyl chloride was consumed during the reaction, the reaction mixture was cooled to 0 ° C. and an aqueous sodium carbonate solution was added. The reaction mixture was extracted with dichloromethane, washed with distilled water and saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was recrystallized and filtered with ethanol to produce 126 g (yield 74%) of the title compound.
1H−NMR(CDCl3,ppm):δ7.0〜8.62(m,14H)、3.6〜4.0(d,2H)、3.4(dd,1H)、3.1〜1.8(m,6H)
[α]D 25=+133.1(c=0.5,MeOH)
融点=100〜100.5℃
〔実施例3.グリシン−Ni−D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノンの製造〕
D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノン(60g,156mmol)、Ni(NO3)2・6H2O(91g,312mmol)、グリシン(58.5g,780mmol)をメタノール(600mL)に溶かした。温度を40〜50℃に加温して反応混合物が緑色に変わった後、水酸化カリウム(61.3g,1.1mol)をメタノール(250mL)に溶かした溶液を滴加した。温度を45〜55℃に維持しつつ1時間攪拌した後、温度を10℃に下げ、酢酸(55mL)をゆっくり滴加した。水を加えて反応混合物を2.5Lにし、6時間攪拌した。生成された固体を濾過して水で洗浄して表記化合物58g(収率75%)を製造した。
1 H-NMR (CDCl 3 , ppm): δ 7.0 to 8.62 (m, 14H), 3.6 to 4.0 (d, 2H), 3.4 (dd, 1H), 3.1 to 1.8 (m, 6H)
[Α] D 25 = + 133.1 (c = 0.5, MeOH)
Melting point = 100-100.5 ° C.
[Example 3. Glycine-Ni-D-2- [Production of N- (N′-benzylprolyl) amino] benzophenone]
D-2- [N- (N′-benzylprolyl) amino] benzophenone (60 g, 156 mmol), Ni (NO 3 ) 2 .6H 2 O (91 g, 312 mmol), glycine (58.5 g, 780 mmol) in methanol (600 mL). After the temperature was raised to 40-50 ° C. and the reaction mixture turned green, a solution of potassium hydroxide (61.3 g, 1.1 mol) in methanol (250 mL) was added dropwise. After stirring for 1 hour while maintaining the temperature at 45-55 ° C, the temperature was lowered to 10 ° C and acetic acid (55 mL) was slowly added dropwise. Water was added to bring the reaction mixture to 2.5 L and stirred for 6 hours. The produced solid was filtered and washed with water to produce 58 g (yield 75%) of the title compound.
1H−NMR(CDCl3,ppm):δ8.2〜6.6(m,14H)、4.4(d,1H)、3.68(s,2H)、3.5(d,1H)、3.9〜1.8(m,7H)
[α]D 25=−2005(c=0.5,MeOH)
〔実施例4.1−ヒドロキシ−1−(3,4−ジベンジルオキシフェニル)グリシン−Ni−D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノンの製造〕
[方法1]乾燥されたフラスコに窒素気流下で、3,4−ジベンジルオキシベンズアルデヒド(18.4g,58mmol)、ナトリウムメトキシド(20mL 28% in MeOH,90mmol)、グリシン−Ni−D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノン(20g,40mmol)、及びメタノール(50mL)を入れて攪拌した。1時間攪拌して反応が完結したことを確認した後、濾過して溶けていない3,4−ジベンジルオキシベンズアルデヒドを除去した。濾液を20%の酢酸(40mL)にゆっくり滴加した後、生成される固体を濾過した。得られた固体を水で洗浄した後、乾燥して赤色の表記化合物26.8g(収率82%)を製造した。
1 H-NMR (CDCl 3 , ppm): δ 8.2 to 6.6 (m, 14H), 4.4 (d, 1H), 3.68 (s, 2H), 3.5 (d, 1H) 3.9 to 1.8 (m, 7H)
[Α] D 25 = −2005 (c = 0.5, MeOH)
Example 4 Production of 1-hydroxy-1- (3,4-dibenzyloxyphenyl) glycine-Ni-D-2- [N- (N′-benzylprolyl) amino] benzophenone
[Method 1] Under a nitrogen stream, 3,4-dibenzyloxybenzaldehyde (18.4 g, 58 mmol), sodium methoxide (20 mL 28% in MeOH, 90 mmol), glycine-Ni-D-2 -[N- (N'-benzylprolyl) amino] benzophenone (20 g, 40 mmol) and methanol (50 mL) were added and stirred. After stirring for 1 hour and confirming that the reaction was completed, undissolved 3,4-dibenzyloxybenzaldehyde was removed by filtration. The filtrate was slowly added dropwise to 20% acetic acid (40 mL) and then the resulting solid was filtered. The obtained solid was washed with water and dried to produce 26.8 g (yield 82%) of the red title compound.
1H−NMR(CDCl3,ppm):δ8.6〜6.0(m,27H)、5.2〜3.5(d,8H)、4.6〜1.4(m,7H)
[α]D 25=+563.2(c=0.5,CHCl3)
[方法2]リチウム(0.18g,25mmol)をメタノール(10mL)に溶解させ、窒素気流下の室温でグリシン−Ni−D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノン(5g,10mmole)を加えた。10分間攪拌した後、3,4−ジベンジルオキシベンズアルデヒド(6.4g,20mmol)を加え、50℃で30分間攪拌した。反応混合物を濾過して溶けていない3,4−ジベンジルオキシベンズアルデヒドを除去した。濾液を20%の酢酸(10mL)にゆっくり滴加した後、生成される固体を濾過した。得られた固体を水で洗浄した後、乾燥して赤色の表記化合物6.53g(80%)を得た。
1 H-NMR (CDCl 3 , ppm): δ 8.6 to 6.0 (m, 27H), 5.2 to 3.5 (d, 8H), 4.6 to 1.4 (m, 7H)
[Α] D 25 = + 563.2 (c = 0.5, CHCl 3 )
[Method 2] Lithium (0.18 g, 25 mmol) was dissolved in methanol (10 mL), and glycine-Ni-D-2- [N- (N'-benzylprolyl) amino] benzophenone (at room temperature under a nitrogen stream) 5 g, 10 mmole) was added. After stirring for 10 minutes, 3,4-dibenzyloxybenzaldehyde (6.4 g, 20 mmol) was added and stirred at 50 ° C. for 30 minutes. The reaction mixture was filtered to remove undissolved 3,4-dibenzyloxybenzaldehyde. The filtrate was slowly added dropwise to 20% acetic acid (10 mL) and then the resulting solid was filtered. The obtained solid was washed with water and dried to obtain 6.53 g (80%) of the red title compound.
1H−NMR(CDCl3,ppm):δ8.6〜6.0(m,27H)、5.2〜3.5(d,8H)、4.6〜1.4(m,7H)
[α]D 25=+563.2(c=0.5,CHCl3)
〔実施例5.L−スレオ−(2S,3R)−3−(3,4−ジベンジルオキシフェニル)セリンの製造〕
1−ヒドロキシ−1−(3,4−ジベンジルオキシフェニル)グリシン−Ni−D−2−[N−(N'−ベンジルプロリル)アミノ]ベンゾフェノン(5g,6mmol)をメタノール(75mL)と5N−塩酸(37.5mL)の混合溶媒に懸濁させ、50℃に加温した。1時間攪拌した後、反応が完結したことを確認した。反応混合物中のメタノールを濃縮し、アンモニア水でpHを6.6とした。生成された固体を濾過して水で洗浄した。固体を完全に乾燥した後、アセトンに懸濁させ, 濾過した。得られた固体を乾燥して表記化合物2.2g(収率93%)を製造した。
1 H-NMR (CDCl 3 , ppm): δ 8.6 to 6.0 (m, 27H), 5.2 to 3.5 (d, 8H), 4.6 to 1.4 (m, 7H)
[Α] D 25 = + 563.2 (c = 0.5, CHCl 3 )
[Example 5. Production of L-threo- (2S, 3R) -3- (3,4-dibenzyloxyphenyl) serine]
1-hydroxy-1- (3,4-dibenzyloxyphenyl) glycine-Ni-D-2- [N- (N′-benzylprolyl) amino] benzophenone (5 g, 6 mmol) in methanol (75 mL) and 5N -Suspended in a mixed solvent of hydrochloric acid (37.5 mL) and heated to 50 ° C. After stirring for 1 hour, it was confirmed that the reaction was complete. The methanol in the reaction mixture was concentrated and the pH was adjusted to 6.6 with aqueous ammonia. The produced solid was filtered and washed with water. The solid was completely dried and then suspended in acetone and filtered. The obtained solid was dried to produce 2.2 g (93% yield) of the title compound.
融点=119.5〜120.4℃
1H−NMR(DMSO−d6,ppm):δ7.25−6.8(m,13H)、5.1(s,4H)、5.0(d,1H)、3.25(d,1H)
〔実施例6.L−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンの製造〕
L−スレオ−3−(3,4−ジベンジルオキシフェニル)セリン(7g,18mmol)をエタノール(400mL)に懸濁させ、濃塩酸(100mL)と10%のPd/C(600mg)を加えた後、1〜2気圧、室温で水素添加分解を行った。反応混合物を濾過してPd/Cを除去し、濾液を濃縮した。得られた反応混合物をエタノールに溶かし、ジエチルアミンとエタノールとの混合溶液でpHを5に調節した。反応混合物を0℃で24時間放置し、生成された固体を濾過した後、エタノールとエーテルとで洗浄して表記化合物3.16g(収率85%)を製造した。
Melting point = 119.5-120.4 ° C.
1 H-NMR (DMSO-d 6 , ppm): δ 7.25-6.8 (m, 13H), 5.1 (s, 4H), 5.0 (d, 1H), 3.25 (d, 1H)
[Example 6. Production of L-threo- (2S, 3R) -3- (3,4-dihydroxyphenyl) serine]
L-threo-3- (3,4-dibenzyloxyphenyl) serine (7 g, 18 mmol) was suspended in ethanol (400 mL), and concentrated hydrochloric acid (100 mL) and 10% Pd / C (600 mg) were added. Thereafter, hydrogenolysis was carried out at 1-2 atm and room temperature. The reaction mixture was filtered to remove Pd / C and the filtrate was concentrated. The obtained reaction mixture was dissolved in ethanol, and the pH was adjusted to 5 with a mixed solution of diethylamine and ethanol. The reaction mixture was allowed to stand at 0 ° C. for 24 hours, and the resulting solid was filtered and washed with ethanol and ether to produce 3.16 g (yield 85%) of the title compound.
1H−NMR(D2O/NaOH,ppm):δ6.5(dd,2H)、6.4(d,1H)、4.7(d,1H)
[α]D 25=−39(c=1,1NHCl)
融点=232〜243℃
1 H-NMR (D 2 O / NaOH, ppm): δ 6.5 (dd, 2H), 6.4 (d, 1H), 4.7 (d, 1H)
[Α] D 25 = −39 (c = 1,1NHCl)
Melting point = 232-243 ° C.
本発明の製造方法は、L−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンまたはその塩の製造に使用され、化学式2及び/または3の化合物は、L−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンまたはその塩の製造での中間体として有用に活用される。 The production method of the present invention is used for the production of L-threo- (2S, 3R) -3- (3,4-dihydroxyphenyl) serine or a salt thereof, and the compound of Formula 2 and / or 3 is L-threo. -(2S, 3R) -3- (3,4-dihydroxyphenyl) serine is usefully utilized as an intermediate in the production of a salt thereof.
Claims (9)
前記化学式1bの化合物のヒドロキシル化反応を行う段階と、を含むL−スレオ−(2S,3R)−3−(3,4−ジヒドロキシフェニル)セリンまたはその塩の製造方法:
Mは、Ni2+ である。 Decomposing the compound of Formula 2 with an acid in a polar organic solvent to obtain a compound of Formula 1b;
A method for producing L-threo- (2S, 3R) -3- (3,4-dihydroxyphenyl) serine or a salt thereof comprising the step of performing a hydroxylation reaction of the compound of Formula 1b:
M is a Ni 2+.
D−プロリンとベンジルクロライドとを反応させてD−N−ベンジルプロリンを製造する段階と、
前記D−N−ベンジルプロリンと2−アミノベンゾフェノンとを反応させてD−2−[N−(N’−ベンジルプロリル)アミノ]ベンゾフェノンを製造する段階と、
前記D−2−[N−(N’−ベンジルプロリル)アミノ]ベンゾフェノン、M(Ni2+
)を含む塩またはその水和物、及びグリシンを反応させる段階と、を含む方法で製造されたものであることを特徴とする請求項6に記載の製造方法。 The compound of Formula 3 is
Reacting D-proline with benzyl chloride to produce DN-benzylproline;
Reacting the DN-benzylproline with 2-aminobenzophenone to produce D-2- [N- (N′-benzylprolyl) amino] benzophenone;
D-2- [N- (N′-benzylprolyl) amino] benzophenone, M (Ni 2+
) Or a hydrate thereof, and a step of reacting glycine, and the method according to claim 6.
及びMは、Ni 2+ である。 Compound of the following chemical formula 2:
And M is a Ni 2+.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040014957A KR100458983B1 (en) | 2004-03-05 | 2004-03-05 | Processes for preparing an optically active serine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005247828A JP2005247828A (en) | 2005-09-15 |
JP4170990B2 true JP4170990B2 (en) | 2008-10-22 |
Family
ID=34918708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005007362A Active JP4170990B2 (en) | 2004-03-05 | 2005-01-14 | Process for producing optically active serine derivatives |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4170990B2 (en) |
KR (1) | KR100458983B1 (en) |
WO (1) | WO2005085178A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105036A1 (en) | 2003-05-12 | 2006-05-18 | Stephen Peroutka | Threo-dops controlled release formulation |
US8158149B2 (en) | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
US20080108830A1 (en) | 2006-11-03 | 2008-05-08 | Ajinomoto Co. Inc | Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound |
ES2500053T3 (en) | 2007-03-09 | 2014-09-29 | Chelsea Therapeutics, Inc. | Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia |
ES2431570T3 (en) * | 2007-05-07 | 2013-11-27 | Chelsea Therapeutics, Inc. | Droxidopa and its pharmaceutical composition for the treatment of attention deficit disorders |
JP5880913B2 (en) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | Treatment for trunk symptoms (postural reflex abnormalities) in Parkinson's disease |
CN103086906B (en) * | 2011-11-03 | 2015-04-01 | 重庆圣华曦药业股份有限公司 | Droxidopa crystal and preparation method thereof |
JP2019511512A (en) * | 2016-03-30 | 2019-04-25 | ピラマル エンタープライジーズ リミテッド | Improved process for producing droxidopa and intermediates thereof |
EP3941917A4 (en) * | 2019-03-22 | 2022-12-21 | Piramal Pharma Limited | An improved process for the preparation of eliglustat and its intermediate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19619510A1 (en) * | 1995-05-18 | 1996-11-21 | Sumitomo Chemical Co | Process for the preparation of threo-3- (3,4-dihydroxyphenyl) serine |
JP3489319B2 (en) * | 1996-03-12 | 2004-01-19 | 住友化学工業株式会社 | Carboxylic acid derivatives, their production and use |
-
2004
- 2004-03-05 KR KR1020040014957A patent/KR100458983B1/en active IP Right Grant
-
2005
- 2005-01-14 JP JP2005007362A patent/JP4170990B2/en active Active
- 2005-03-04 WO PCT/KR2005/000604 patent/WO2005085178A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2005247828A (en) | 2005-09-15 |
WO2005085178A1 (en) | 2005-09-15 |
KR100458983B1 (en) | 2004-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5202519B2 (en) | (R)-(−)-3- (Carbamoylmethyl) -5-methylhexanoic acid, pregabalin, and synthetic intermediate production method | |
KR20050113292A (en) | Process for the preparation of optically pure 4-hydroxy-2-oxo-1-pyrrolidineacetamide | |
JP2005531633A (en) | Preparation of chiral aminonitrile | |
JP4170990B2 (en) | Process for producing optically active serine derivatives | |
JP2001519385A (en) | Method for producing chiral compound | |
JP6966656B2 (en) | Intermediates of optically active piperidine derivatives and methods for producing them | |
EP2019097A1 (en) | Process for preparing (alphaS)-alpha-(2-methylpropyl)-2-(1-piperidinyl)benzenemethanamine | |
US20070129443A1 (en) | Production method of aminochlorohydrin sulfate | |
KR20080046176A (en) | Method of obtaining phenyl carbamates | |
JP6239751B2 (en) | Method for producing lacosamide | |
JP4143787B2 (en) | Method for producing α-aminohalomethyl ketone derivative | |
JP4427266B2 (en) | β-alanine derivative and method for producing the same | |
JP2000178253A (en) | Production of optically active pipecolic acid | |
JP3005669B2 (en) | Method for producing asymmetric fluorinated primary amines | |
US20190127315A1 (en) | Method for preparing d-4,4'-biphenylalanine alkyl ester or l-4,4'-biphenylalanine alkyl ester from dl-4,4'-biphenylalanine alkyl ester | |
WO2011076915A1 (en) | Novel method for the preparation of (s)-pregabalin field of the invention | |
EP2739610B1 (en) | Process for the manufacture of ivabradine and of intermediates of synthesis thereof | |
KR101085170B1 (en) | Method of Preparing S-Rivastigmine | |
JP4126921B2 (en) | Process for producing optically active β-phenylalanine derivative | |
JP2002003453A (en) | METHOD FOR PURIFYING OPTICALLY ACTIVE alpha-METHYL- BIS-3,5-(TRIFLUOROMETHYL) BENZYLAMINES | |
JP2002371060A (en) | Method for producing optically active aminopiperidine derivative | |
JPH11279159A (en) | Production of optically active piperazinecarboxlic acid ester | |
JP5510040B2 (en) | Optical resolution to obtain optically active (R) -1- (4-fluorophenyl) ethylamine | |
JP2003137835A (en) | Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid | |
JP2002512210A (en) | Method for producing 2-hydroxyalkylhalophenone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080514 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080619 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080715 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080807 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110815 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4170990 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110815 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120815 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120815 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130815 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |